Compare Apple Inc (AAPL) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apple Inc vs BioNTech SE - ADR — how do they compare? Apple Inc trades at $304.41 (market cap $4.50T), while BioNTech SE - ADR trades at $92.64 (market cap $23.31B). The key difference: Apple Inc is far larger — about 193.1× BioNTech SE - ADR's market cap, and Apple Inc pays a 0.35% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| AAPL | BNTX | |
|---|---|---|
Market Cap | $4.50T | $23.31B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $340.08 | $119.34 |
52-Week Low | $224.90 | $83.89 |
Enterprise Value | $4.52T | $6.60B |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAPL trades at $308.26, down 1.62% on the day, with a bearish technical signal and support near $306. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $1.98. Revenue grew to $416.16B in 2025, and net income margin improved to 27.62%. Recent news highlights AI potential through a partnership with Alphabet's Gemini, but store closures and union disputes pose headwinds.
Outlook remains positive with a consensus price target of $337.63, implying 9.5% upside, supported by robust cash flow and a 63.6% buy rating from analysts. Risks include weaker iPhone sales, regulatory fines, and competitive pressures in AI. The stock offers growth potential but requires monitoring of execution risks and macroeconomic trends.
BioNTech (BNTX) trades at $93.67, up 2.72% today, with a bullish technical signal and strong analyst support. The stock faces fundamental challenges, including declining COVID-19 vaccine revenue and negative profitability, but holds a robust cash position of $16.78 billion. Recent news highlights leadership changes and pipeline advancements in oncology, with a consensus price target of $121.00 implying significant upside potential.
Outlook: Long-term growth hinges on oncology pipeline success, but near-term risks from vaccine demand volatility and net losses persist. Investment opportunity lies in discounted valuation relative to cash and pipeline assets, though execution risks and competitive pressures require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
